Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.


:Long non-coding ribonucleic acids (RNAs) are a novel class of RNA molecules, which are increasingly recognized as important molecular players in solid and hematologic malignancies. Herein we investigated whether long non-coding RNA expression is associated with clinical and molecular features, as well as outcome of younger adults (aged <60 years) with de novo cytogenetically normal acute myeloid leukemia. Whole transcriptome profiling was performed in a training (n=263) and a validation set (n=114). Using the training set, we identified 24 long non-coding RNAs associated with event-free survival. Linear combination of the weighted expression values of these transcripts yielded a prognostic score. In the validation set, patients with high scores had shorter disease-free (P<0.001), overall (P=0.002) and event-free survival (P<0.001) than patients with low scores. In multivariable analyses, long non-coding RNA score status was an independent prognostic marker for disease-free (P=0.01) and event-free survival (P=0.002), and showed a trend for overall survival (P=0.06). Among multiple molecular alterations tested, which are prognostic in cytogenetically normal acute myeloid leukemia, only double CEBPA mutations, NPM1 mutations and FLT3-ITD associated with distinct long non-coding RNA signatures. Correlation of the long non-coding RNA scores with messenger RNA and microRNA expression identified enrichment of genes involved in lymphocyte/leukocyte activation, inflammation and apoptosis in patients with high scores. We conclude that long non-coding RNA profiling provides meaningful prognostic information in younger adults with cytogenetically normal acute myeloid leukemia. In addition, expression of prognostic long non-coding RNAs associates with oncogenic molecular pathways in this disease. Identifier: 00048958 (CALGB-8461), 00899223 (CALGB-9665), and 00900224 (CALGB-20202).






Papaioannou D,Nicolet D,Volinia S,Mrózek K,Yan P,Bundschuh R,Carroll AJ,Kohlschmidt J,Blum W,Powell BL,Uy GL,Kolitz JE,Wang ES,Eisfeld AK,Orwick SJ,Lucas DM,Caligiuri MA,Stone RM,Byrd JC,Garzon R,Bloomfield CD




Has Abstract


2017-08-01 00:00:00














  • Identification of chromosomal translocations in leukemias by hybridization with oligonucleotide microarrays.

    abstract:BACKGROUND AND OBJECTIVES:Identification of chromosomal rearrangements is important for a precise risk-stratified diagnosis of hematologic malignancies. As the number of known translocations, specific for different types of leukemia increases, it takes ever more time and increasing amounts of patient's material to scre...


    pub_type: 杂志文章


    authors: Nasedkina T,Domer P,Zharinov V,Hoberg J,Lysov Y,Mirzabekov A

    更新日期:2002-04-01 00:00:00

  • Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys.

    abstract::Multicytokine therapy may be useful to counteract radiation-induced myelosuppression. We assessed the stem cell factor + glycosylated erythropoietin + pegylated granulocyte colony-stimulating factor combination (SEG) as an emergency treatment. SEG in highly irradiated monkeys efficacy appeared to be restricted to gran...


    pub_type: 信件


    authors: Drouet M,Delaunay C,Grenier N,Garrigou P,Mayol JF,Hérodin F

    更新日期:2008-03-01 00:00:00

  • A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

    abstract::Immune dysregulation is a mechanism contributing to ineffective hematopoiesis in a subset of myelodysplastic syndrome patients. We report the first US multicenter non-randomized, phase II trial examining the efficacy of rabbit(r)-anti-thymocyte globulin using 2.5 mg/kg/day administered daily for 4 doses. The primary e...


    pub_type: 杂志文章,多中心研究


    authors: Komrokji RS,Mailloux AW,Chen DT,Sekeres MA,Paquette R,Fulp WJ,Sugimori C,Paleveda-Pena J,Maciejewski JP,List AF,Epling-Burnette PK

    更新日期:2014-07-01 00:00:00

  • Red blood cell metabolism in Rhesus macaques and humans: comparative biology of blood storage.

    abstract::Macaques are emerging as a critical animal model in transfusion medicine, because of their evolutionary similarity to humans and perceived utility in discovery and translational science. However, little is known about the metabolism of Rhesus macaque red blood cells (RBC) and how this compares to human RBC metabolism ...


    pub_type: 杂志文章


    authors: Stefanoni D,Shin HKH,Baek JH,Champagne DP,Nemkov T,Thomas T,Francis RO,Zimring JC,Yoshida T,Reisz JA,Spitalnik SL,Buehler PW,D'Alessandro A

    更新日期:2020-08-01 00:00:00

  • Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.

    abstract:BACKGROUND:Dyskeratosis congenita is a cancer-prone bone marrow failure syndrome caused by aberrations in telomere biology. DESIGN AND METHODS:We studied 65 patients with dyskeratosis congenita and 127 unaffected relatives. Telomere length was measured by automated multicolor flow fluorescence in situ hybridization in...


    pub_type: 临床试验,杂志文章


    authors: Alter BP,Rosenberg PS,Giri N,Baerlocher GM,Lansdorp PM,Savage SA

    更新日期:2012-03-01 00:00:00

  • Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.

    abstract::We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker...


    pub_type: 信件


    authors: Kainz B,Fonatsch C,Schwarzinger I,Sperr WR,Jäger U,Gaiger A

    更新日期:2005-05-01 00:00:00

  • Submicroscopic deletions at 7q region are associated with recurrent chromosome abnormalities in acute leukemia.

    abstract:BACKGROUND AND OBJECTIVES:Loss of heterozygosity (LOH) on the long arm of chromosome 7 (7q) has been frequently reported in several types of human cancer including hematologic malignancies. Moreover, monosomy of chromosome 7 and 7q deletions have been associated in acute myeloid leukemia (AML) with aggressive disease a...


    pub_type: 杂志文章


    authors: Basiricò R,Pirrotta R,Fabbiano F,Mirto S,Cascio L,Pagano M,Cammarata G,Magrin S,Santoro A

    更新日期:2003-04-01 00:00:00

  • Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma.

    abstract::Translocation t(9;14)(p13;q32) involving PAX5 and IGH genes was first described in lymphoplasmacytic lymphoma. New data suggest that this translocation is not restricted to a specific morphologic subtype but occurs in other B-cell lymphomas. We present three cases with a diagnosis of splenic marginal zone lymphoma and...


    pub_type: 信件


    authors: Baró C,Salido M,Domingo A,Granada I,Colomo L,Serrano S,Solé F

    更新日期:2006-09-01 00:00:00

  • HIV-related Hodgkin's disease. Report of nine cases.

    abstract:BACKGROUND:The association between lymphoproliferative disease and AIDS is now well known, but only non-Hodgkin's lymphomas (LNH) are surely related to HIV infection. Hodgkin's disease (HD) occurs rarely in HIV seropositives, so it is impossible to establish a connection between AIDS and this neoplasm. METHODS AND RES...


    pub_type: 杂志文章


    authors: Novati S,Malfitano A,Sacchi P,Patruno SF,Tornari PM,Rondanelli EG

    更新日期:1993-01-01 00:00:00

  • Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

    abstract::Systemic AL amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly but treatment and outcomes have not been systematically studied in this group of patients in whom comorbidities and frailty may compound morbidity and mortality. We report the outcomes of 295 pat...


    pub_type: 临床试验,杂志文章


    authors: Sachchithanantham S,Offer M,Venner C,Mahmood SA,Foard D,Rannigan L,Lane T,Gillmore JD,Lachmann HJ,Hawkins PN,Wechalekar AD

    更新日期:2015-11-01 00:00:00

  • Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

    abstract::We previously reported initial results in 102 multiple myeloma (MM) patients treated with sequential high-dose melphalan and autologous hematopoietic cell transplantation followed by 200 cGy total body irradiation with or without fludarabine 90 mg/m2 and allogeneic hematopoietic cell transplantation. Here we present l...


    pub_type: 杂志文章


    authors: Maffini E,Storer BE,Sandmaier BM,Bruno B,Sahebi F,Shizuru JA,Chauncey TR,Hari P,Lange T,Pulsipher MA,McSweeney PA,Holmberg L,Becker PS,Green DJ,Mielcarek M,Maloney DG,Storb R

    更新日期:2019-02-01 00:00:00

  • High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation.

    abstract::HLA molecules play an important role for immunoreactivity in allogeneic hematopoietic stem cell transplantation. To elucidate the effect of specific HLA alleles on acute graft-versus-host disease, we conducted a retrospective analysis using 6967 Japanese patients transplanted with T-cell-replete marrow from an unrelat...


    pub_type: 杂志文章


    authors: Morishima S,Kashiwase K,Matsuo K,Azuma F,Yabe T,Sato-Otsubo A,Ogawa S,Shiina T,Satake M,Saji H,Kato S,Kodera Y,Sasazuki T,Morishima Y,Japan Marrow Donor Program.

    更新日期:2016-04-01 00:00:00

  • Hepcidin: from discovery to differential diagnosis.

    abstract::Although iron is essential for living organisms to survive, its reactive properties require strict regulation in order to prevent toxic effects. Hepcidin, a liver produced peptide hormone, is thought to be the central regulator of body iron metabolism. Its production is mainly controlled by the erythropoietic activity...


    pub_type: 杂志文章,评审


    authors: Kemna EH,Tjalsma H,Willems HL,Swinkels DW

    更新日期:2008-01-01 00:00:00

  • Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.

    abstract::Arecent source data meta-analysis of randomized trials in adults assessing the immunoconjugate gemtuzumab ozogamicin combined with standard chemotherapy in acute myeloid leukemia showed a significant survival benefit in patients without an adverse karyotype. It is not clear whether the optimal dose should be 3 mg/m(2)...


    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Burnett A,Cavenagh J,Russell N,Hills R,Kell J,Jones G,Nielsen OJ,Khwaja A,Thomas I,Clark R,UK NCRI AML Study Group.

    更新日期:2016-06-01 00:00:00

  • Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

    abstract::Diagnostic biomarkers can be used to determine relapse risk in acute myeloid leukemia, and certain genetic aberrancies have prognostic relevance. A diagnostic immunophenotypic expression profile, which quantifies the amounts of distinct gene products, not just their presence or absence, was established in order to imp...


    pub_type: 临床试验,杂志文章,多中心研究


    authors: Voigt AP,Brodersen LE,Alonzo TA,Gerbing RB,Menssen AJ,Wilson ER,Kahwash S,Raimondi SC,Hirsch BA,Gamis AS,Meshinchi S,Wells DA,Loken MR

    更新日期:2017-12-01 00:00:00

  • CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.

    abstract::Twenty-five adult patients with resistant or early relapsing Hodgkin's disease have been treated with CAV combination chemotherapy (CCNU, melphalan and etoposide). All patients had previously received both MOPP and ABVD regimens (23 patients as primary therapy and two as first salvage). High-energy radiotherapy had be...


    pub_type: 杂志文章


    authors: Brusamolino E,Castelli G,Pagnucco G,Orlandi E,Malagó D,Lazzarino M,Bernasconi C

    更新日期:1990-07-01 00:00:00

  • Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.

    abstract:BACKGROUND AND OBJECTIVE:Idarubicin (IDA) is relatively immune to the multidrug resistance P-gp mechanism that is frequently expressed in recurrent and refractory hematologic malignancies. Owing to rapid metabolism in vivo, a continuous infusion (CI) of IDA might prolong exposure time to the parent drug rather than its...


    pub_type: 临床试验,杂志文章


    authors: Bassan R,Chiodini B,Zucchetti M,Lerede T,Cornelli PE,Cortelazzo S,Barbui T

    更新日期:1998-01-01 00:00:00

  • SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

    abstract::Mastocytosis is a rare and chronic disease with phenotypes ranging from indolent to severe. Prognosis for this disease is variable and very few biomarkers to predict disease evolution or outcome are currently known. We have performed comprehensive screening in our large cohort of mastocytosis patients for mutations pr...


    pub_type: 杂志文章,多中心研究


    authors: Hanssens K,Brenet F,Agopian J,Georgin-Lavialle S,Damaj G,Cabaret L,Chandesris MO,de Sepulveda P,Hermine O,Dubreuil P,Soucie E

    更新日期:2014-05-01 00:00:00

  • Autoimmunity and the risk of myeloproliferative neoplasms.

    abstract::The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of ...


    pub_type: 杂志文章


    authors: Kristinsson SY,Landgren O,Samuelsson J,Björkholm M,Goldin LR

    更新日期:2010-07-01 00:00:00

  • High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.

    abstract::We evaluate the long-term results of a prospective clinical study enrolling more than 100 adult patients with Burkitt lymphoma/leukemia. Depending on extent of disease, treatment consisted of six to eight rituximab infusions and four to six courses of intensive chemotherapy (attenuated in patients aged >55 years) with...


    pub_type: 临床试验,杂志文章,多中心研究


    authors: Intermesoli T,Rambaldi A,Rossi G,Delaini F,Romani C,Pogliani EM,Pagani C,Angelucci E,Terruzzi E,Levis A,Cassibba V,Mattei D,Gianfaldoni G,Scattolin AM,Di Bona E,Oldani E,Parolini M,Gökbuget N,Bassan R

    更新日期:2013-11-01 00:00:00

  • Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia.

    abstract:BACKGROUND AND OBJECTIVES:Aberrant promoter methylation targets CpG islands causing gene silencing. We explored aberrant promoter methylation of genes potentially involved in B-cell malignancies and encoding proteins implicated in DNA repair (O6-methylguanine-DNA methyltransferase, MGMT), detoxification of environmenta...


    pub_type: 杂志文章


    authors: Rossi D,Capello D,Gloghini A,Franceschetti S,Paulli M,Bhatia K,Saglio G,Vitolo U,Pileri SA,Esteller M,Carbone A,Gaidano G

    更新日期:2004-02-01 00:00:00

  • Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies.

    abstract::Spontaneous Rh blood group changes are a striking sign, reported to occur mainly in patients with hematologic disorders. Upon routine blood grouping, 2 unrelated individuals showed unexplained mixed red cell phenotype regarding the highly immunogenic c antigen (RH4), clinically relevant for blood transfusion and fetom...


    pub_type: 杂志文章


    authors: Dauber EM,Mayr WR,Hustinx H,Schönbacher M,Budde H,Legler TJ,König M,Haas OA,Fritsch G,Körmöczi GF

    更新日期:2019-03-01 00:00:00

  • Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

    abstract:BACKGROUND:In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied ...


    pub_type: 杂志文章,随机对照试验


    authors: Buyse M,Michiels S,Squifflet P,Lucchesi KJ,Hellstrand K,Brune ML,Castaigne S,Rowe JM

    更新日期:2011-08-01 00:00:00

  • Fibrin(ogen) in human disease: both friend and foe.

    abstract::Fibrinogen is an abundant protein synthesized in the liver, present in human blood plasma at concentrations ranging from 1.5-4 g/L in healthy individuals with a normal half-life of 3-5 days. With fibrin, produced by thrombin-mediated cleavage, fibrinogen plays important roles in many physiological processes. Indeed, t...


    pub_type: 杂志文章,评审


    authors: Vilar R,Fish RJ,Casini A,Neerman-Arbez M

    更新日期:2020-01-31 00:00:00

  • Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis.

    abstract::The coexistence of chronic myeloid leukemia (CML) and B-cell chronic lymphocytic leukemia (CLL) in the same patient is rare. A 71-year-old woman developed a B-lineage lymphoid blast crisis at 18 months after diagnosis of Ph-positive CML. At this time, a lymphoid cell population with morphologic and immunophenotypic fe...


    pub_type: 杂志文章,评审


    authors: Esteve J,Cervantes F,Rives S,Rozman M,Zarco MA,Montserrat E

    更新日期:1997-09-01 00:00:00

  • Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.

    abstract:BACKGROUND:In multiple myeloma, expression of cancer testis antigens may provide prognostic markers and potential targets for immunotherapy. Expression at relapse has not yet been evaluated for a large panel of cancer testis antigens which can be classified by varying expression in normal tissue: restricted to testis, ...


    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: van Duin M,Broyl A,de Knegt Y,Goldschmidt H,Richardson PG,Hop WC,van der Holt B,Joseph-Pietras D,Mulligan G,Neuwirth R,Sahota SS,Sonneveld P

    更新日期:2011-11-01 00:00:00

  • Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests.

    abstract::Conventional coagulation tests might be inadequate to explore mechanisms regulating thrombin generation in neonates, because they do not allow full activation of the reduced levels of protein C. Therefore, they do not reflect the action of pro- and anti-coagulants as does the endogenous thrombin potential assessed in ...


    pub_type: 杂志文章


    authors: Tripodi A,Ramenghi LA,Chantarangkul V,De Carli A,Clerici M,Groppo M,Mosca F,Mannucci PM

    更新日期:2008-08-01 00:00:00

  • Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition.

    abstract:BACKGROUND:Non-Hodgkin's lymphomas are a heterogeneous group of neoplasms arising from the lymphopoietic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few established risk factors for the development of these neoplasms include viral infections and immunological abnormalities, but t...


    pub_type: 杂志文章


    authors: Khan AE,Gallo V,Linseisen J,Kaaks R,Rohrmann S,Raaschou-Nielsen O,Tjønneland A,Johnsen HE,Overvad K,Bergmann MM,Boeing H,Benetou V,Psaltopoulou T,Trichopoulou A,Masala G,Mattiello A,Grioni S,Tumino R,Vermeulen RC,Pe

    更新日期:2008-06-01 00:00:00

  • Dendritic cells: specialized antigen presenting cells.

    abstract::Renewing interest in cancer immunotherapy reflects the excellent results that have been obtained in animal models and the promising results in early clinical trails with dendritic cell (DC) based approaches. The central role that DCs play in the initiation of an immune response raises the possibility of using them to ...


    pub_type: 杂志文章,评审


    authors: Di Nicola M,Lemoli RM

    更新日期:2000-02-01 00:00:00

  • A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

    abstract::Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase. Sequential inhibition of ribonu...


    pub_type: 杂志文章


    authors: Zeidner JF,Karp JE,Blackford AL,Smith BD,Gojo I,Gore SD,Levis MJ,Carraway HE,Greer JM,Ivy SP,Pratz KW,McDevitt MA

    更新日期:2014-04-01 00:00:00